(Q41127907)

27 September 2017

1 reference

title

Definition and epidemiology of treatment-resistant depression (English)

1 reference

27 September 2017

1 reference

Fava M

1

1 reference

PubMed ID

8827185

27 September 2017

Davidson KG

series ordinal

2

1 reference

27 September 2017

1 June 1996

1 reference

Psychiatric Clinics of North America

27 September 2017

1 reference

27 September 2017

19

1 reference

27 September 2017

179-200

1 reference

27 September 2017

2

1 reference

Chronic depressions. Part 1. Clinical and familial characteristics in 137 probands

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Fluoxetine efficacy in treatment resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Proposed delusional depression subtypes: preliminary evidence from a retrospective study of phenomenology and treatment course.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Chronicity in major depression. A naturalistic prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Follow-up and family study of anxious depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Relationship of patient background characteristics to efficacy of pharmacotherapy in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Long-term treatment of major depressive disorder with paroxetine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A comparison of paroxetine and placebo in depressed outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Treatment-resistant depression: a critique of current approaches.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Personality disorder comorbidity with major depression and response to fluoxetine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A cluster-analytically derived subtyping of chronic affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Moclobemide versus fluoxetine for major depressive episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Analysis of time to stabilization in the treatment of depression: biological and clinical correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

The clinical meaning of refractory depression: a review for the clinician

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Unrecognized physical illness prompting psychiatric admission: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

The impact of an uncaring partner on improvement in non-melancholic depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Anxious and nonanxious depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Temperament predicts clomipramine and desipramine response in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Recovery and major depression: factors associated with twelve-month outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression).

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Long-term Outcome of Episodes of Major Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

"Double depression": two-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Alprazolam and amitriptyline in the treatment of moderate depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

The long-term outcome of Maudsley depressives

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Therapy-resistant depressions - a clinical classification.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Antidepressant specificity in atypical depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Treatment resistant depression: a clinical perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Desipramine for the treatment of "pure" dysthymia versus "double" depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Treatments of depression and the functional capacity to work.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Depressed outpatients' life contexts, amount of treatment, and treatment outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Seasonality in atypical depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

The outcome of antidepressant use in the medically ill

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

The importance of dosage in prescribing antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Duration of antidepressant drug treatment. What is an adequate trial?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Moclobemide versus fluoxetine for a major depressive episode

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Moclobemide (Aurorix) in primary major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Delusional depression. A one year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Factors associated with 1-year outcome of major depression in the community.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Epidemiology, demography and definitions

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

The Newcastle Chronic Depression Study. Patient characteristics and factors associated with chronicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Can we predict the persistence of depression?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Sleep deprivation accelerates the response to nortriptyline.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Effect of fluoxetine on dexamethasone-induced growth hormone release in depression: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Anxious depressions. Clinical, family history, and naturalistic outcome--comparisons with panic and major depressive disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Treatment resistant depression in an Australian context. I: The utility of the term and approaches to management.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Comorbidity of personality disorders and depression: implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

Life stressors, social resources, coping, and the 4-year course of unipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970283-5

7 January 2021

10.1016/S0193-953X(05)70283-5

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8827185